Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled tr... von Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., de Loredo, L., Tornøe, K., Boopalan, A., Nauck, M. A.

Volltext

P292 Efficacité et tolérance de l’adjonction du liraglutide à une insuline basale en comparaison au placebo chez des patients diabétiques de type 2 (résultats de l’essai randomisé... von Bouzidi, A, Lahtela, J, Ahmann, A, Rodbard, H, De Loredo, L, Tornøe E, K, Boopalan, A, Nauck, M

Volltext

PO410 EFFICACY AND SAFETY OF LIRAGLUTIDE VS PLACEBO WHEN ADDED TO BASAL INSULIN ANALOGUES IN SUBJECTS WITH TYPE 2 DIABETES (LIRA-ADD2BASAL): A RANDOMISED, PLACEBO-CONTROLLED TRIAL von Ahmann, A, Rosenstock, J, Rodbard, H, Lahtela, J, de Loredo, L, Tornøe, K, Wang, F, Nauck, M

Volltext

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes von Zinman, Bernard, Wanner, Christoph, Lachin, John M, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Inzucchi, Silvio E

Volltext

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes von Wanner, Christoph, Inzucchi, Silvio E, Lachin, John M, Fitchett, David, von Eynatten, Maximilian, Mattheus, Michaela, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Zinman, Bernard

Volltext

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial von Fitchett, David, Zinman, Bernard, Wanner, Christoph, Lachin, John M, Hantel, Stefan, Salsali, Afshin, Johansen, Odd Erik, Woerle, Hans J, Broedl, Uli C, Inzucchi, Silvio E

Volltext

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease von Wanner, Christoph, Lachin, John M, Inzucchi, Silvio E, Fitchett, David, Mattheus, Michaela, George, Jyothis, Woerle, Hans J, Broedl, Uli C, von Eynatten, Maximilian, Zinman, Bernard

Volltext

Prevalence of diabetes, obesity, hypertension and hyperlipidemia in the central area of Argentina von De Sereday, MS, Gonzalez, C, Giorgini, D, De Loredo, L, Braguinsky, J, Cobeñas, C, Libman, C, Tesone, C

Volltext

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial von Wanner, Christoph, Heerspink, Hiddo J L, Zinman, Bernard, Inzucchi, Silvio E, Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C, von Eynatten, Maximilian, Groop, Per-Henrik

Volltext

Estudio oncativo: factores de riesgo psicopatológicos de enfermedad arterial (prevalencia, superposición o vínculo con otros factores) von RJ Madoery, HA Luquez, L De Loredo, DJ Carri, H Roiter, G Bauducco, L Bilbao, P Brousset, A Dávila, ME Fissone, S Herrero, O Luchino, F Nucíforo

Volltext

Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　― Results From EMPA-REG OUTCOME von Kaku, Kohei, Lee, Jisoo, Mattheus, Michaela, Kaspers, Stefan, George, Jyothis, Woerle, Hans-Juergen, on behalf of the EMPA-REG OUTCOME® Investigators

Volltext

Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes von Verma, Subodh, Wanner, Christoph, Zwiener, Isabella, Ofstad, Anne Pernille, George, Jyothis T., Fitchett, David, Zinman, Bernard

Volltext

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose von The DREAM Trial Investigators

Volltext

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose : Results of the Diabetes REduction... von Dagenais, G R, Gerstein, H C, Holman, R, Budaj, A, Escalante, A, Hedner, T, Keltai, M, Lonn, E, McFarlane, S, McQueen, M, Teo, K, Sheridan, P, Bosch, J, Pogue, J, Yusuf, S

Volltext

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction... von Gerstein, Hertzel, Yusuf, Salim, Riddle, Matthew C, Ryden, Lars, Bosch, Jackie

Volltext

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial von Gerstein, H C, Yusuf, S, Holman, R, Bosch, J, Pogue, J

Volltext

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes von Gerstein, H C, Mohan, V, Avezum, A, Bergenstal, R M, Chiasson, J-L, Garrido, M, MacKinnon, I, Rao, P V, Zinman, B, Jung, H, Joldersma, L, Bosch, J, Yusuf, S

Volltext

Psycho-pathological risk factor of arterial disease (prevalence, superposition or vinculation with other factors) von Madoery, R J, Luquez, H A, De Loredo, L, Carri, D J, Roiter, H, Bauducco, G, Bilbao, L, Brousset, P, Dávila, A, Fissone, M E, Herreros, S, Luchino, O, Nuciforo, F

Volltext

Near-optimal single-photon sources in the solid state von Somaschi, N., Giesz, V., De Santis, L., Loredo, J. C., Almeida, M. P., Hornecker, G., Portalupi, S. L., Grange, T., Antón, C., Demory, J., Gómez, C., Sagnes, I., Lanzillotti-Kimura, N. D., Lemaítre, A., Auffeves, A., White, A. G., Lanco, L., Senellart, P.

Volltext

Generation of non-classical light in a photon-number superposition von Loredo, J. C., Antón, C., Reznychenko, B., Hilaire, P., Harouri, A., Millet, C., Ollivier, H., Somaschi, N., De Santis, L., Lemaître, A., Sagnes, I., Lanco, L., Auffèves, A., Krebs, O., Senellart, P.

Volltext